| 000 | 02936 a2200685 4500 | ||
|---|---|---|---|
| 005 | 20250515050516.0 | ||
| 264 | 0 | _c20070424 | |
| 008 | 200704s 0 0 eng d | ||
| 022 | _a1699-048X | ||
| 024 | 7 |
_a10.1007/s12094-006-0136-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJantus-Lewintre, Eloisa | |
| 245 | 0 | 0 |
_aBortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. _h[electronic resource] |
| 260 |
_bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _cNov 2006 |
||
| 300 |
_a805-11 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aADP-ribosyl Cyclase 1 _xbiosynthesis |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAmino Acid Chloromethyl Ketones _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBoronic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aBortezomib |
| 650 | 0 | 4 | _aCaspase Inhibitors |
| 650 | 0 | 4 |
_aCaspases _xphysiology |
| 650 | 0 | 4 |
_aCysteine Proteinase Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Rearrangement, B-Lymphocyte, Heavy Chain |
| 650 | 0 | 4 | _aGenes, Immunoglobulin |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aI-kappa B Kinase _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aI-kappa B Proteins _xmetabolism |
| 650 | 0 | 4 |
_aImmunoglobulin Heavy Chains _xgenetics |
| 650 | 0 | 4 |
_aImmunoglobulin Variable Region _xgenetics |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xgenetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNF-kappa B _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNitriles _xpharmacology |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aProtein Processing, Post-Translational _xdrug effects |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-6 _xgenetics |
| 650 | 0 | 4 |
_aPyrazines _xadministration & dosage |
| 650 | 0 | 4 |
_aSulfones _xpharmacology |
| 650 | 0 | 4 |
_aTumor Cells, Cultured _xdrug effects |
| 650 | 0 | 4 |
_aZAP-70 Protein-Tyrosine Kinase _xbiosynthesis |
| 700 | 1 | _aSarsotti, Elena | |
| 700 | 1 | _aTerol, María José | |
| 700 | 1 | _aBenet, Isabel | |
| 700 | 1 | _aGarcía-Conde, Javier | |
| 773 | 0 |
_tClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico _gvol. 8 _gno. 11 _gp. 805-11 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12094-006-0136-3 _zAvailable from publisher's website |
| 999 |
_c16705418 _d16705418 |
||